Amy Langer on Leave of Absence From NABCO After Automobile Accident

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK--Amy S. Langer, of the National Alliance of Breast Cancer Organizations (NABCO), has taken a leave of absence from her position as executive director, due to extensive injuries suffered in a serious car accident in upstate New York.

NEW YORK--Amy S. Langer, of the National Alliance of Breast CancerOrganizations (NABCO), has taken a leave of absence from her positionas executive director, due to extensive injuries suffered in aserious car accident in upstate New York.

The NABCO Board of Directors said in a press release that Ms.Langer is expected to recover sufficiently to return to NABCOonce her treatment and rehabilitation have concluded. During thisperiod, Betsy Gardella, NABCO's associate executive director,will assume Ms. Langer's responsibilities as acting executivedirector.

The members of NABCO's board "are deeply saddened by theaccident and express their support to Ms. Langer and her family."The staff of Oncology News International and everyone at PRR,Inc. also wish to convey their concern for Ms. Langer and offertheir support and prayers for her and her family.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content